Pure Global
NCT06248359

Association Between Postoperative Administration of L-Arginine and CSA-AKI

Association Between Early Postoperative L-Arginine Administration and Acute Kidney Injury Following Cardiac Surgery
Xijing Hospital·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
L-Arginine hydrochloride
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Xijing Hospital
Location
Xi'an, China
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Mar 01, 2024
Enrollment
7000 participants
Primary outcome

incidence of postoperative AKI

Summary

To investigate the association between the the early administration of L-Arginine after
 CPB-assisted cardiac surgery and the incidence of CS-AKI in adult patients. To test if it can
 reduce the incidence of post-operative AKI.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06248359
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06248359 through Pure Global AI's free database. This phase not specified trial is sponsored by Xijing Hospital and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 7000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.